BIT225 trial did not fail.
It was not expected to improve reduction in HIV in the blood over existing ART.
It was tested to see effect against HIV in macrophages and successful against HIV in those reservoirs.
Siginificant outcome.
Excellent safety and well tolerated by HIV subjects.
More beneficial outcome to patients with BIT225 in combination with ART.
Doesn't sound like a failure to me.
So I hold BIT and will hold.
